Citius Oncology Announces Positive Phase 1 Data for LYMPHIR in Gynecologic Cancers, Expanding Potential Indications
CTOR sits 83% above its 52-week low of $0.551 on light trading volume (0.3× avg).
Summary
Citius Oncology reported positive topline results from an investigator-initiated Phase 1 study of LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic cancers, showing favorable safety and promising efficacy signals.
Key Events · Product Development and Regulatory · CTOR
-
Positive Phase 1 Clinical Trial Results
Citius Oncology announced positive topline results from an investigator-initiated Phase 1 study evaluating LYMPHIR™ (denileukin diftitox-cxdl) in combination with pembrolizumab for recurrent or refractory gynecologic cancers.
-
Promising Efficacy Signals
The study demonstrated a 24% objective response rate (ORR) and a 48% clinical benefit rate (CBR) among evaluable patients, suggesting augmented anti-tumor activity in a heavily pretreated population.
-
Favorable Safety Profile
No unexpected safety signals or serious immune-related adverse events were observed at any dose level of LYMPHIR in combination with pembrolizumab.
-
Potential for Expanded Indications
The positive data signals LYMPHIR's potential to augment immune checkpoint inhibitor efficacy in gynecologic cancers, a significant unmet medical need, potentially expanding its utility beyond its FDA-approved indication for CTCL.
Analysis · CTOR · Life Sciences
This announcement of positive Phase 1 clinical trial results for LYMPHIR in recurrent or refractory gynecologic cancers is highly significant for Citius Oncology, especially given the company's previously disclosed 'going concern' warning. The favorable safety profile and promising efficacy signals (24% ORR, 48% CBR) in a heavily pretreated patient population with limited treatment options could substantially broaden LYMPHIR's market potential beyond its approved CTCL indication. For a small biotech facing financial runway challenges, such positive data can be critical for attracting partnerships, securing future financing, and extending the company's operational viability.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTOR was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $89.2M. The 52-week trading range was $0.55 to $6.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.